Preclinical data are promising but not yet clinical proof-of-concept. Monitor upcoming Phase 1 readouts for NX-1607 and NRX-0305 as next major catalysts. The absence of clinical efficacy data means current valuation relies heavily on platform optimism, leaving stock vulnerable to future setbacks.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $16.63entry
- T+1 · 7mo ago −0.36%α +0.03% · $16.57
- T+5 · 7mo ago +0.36%α +0.31% · $16.69
- T+20 · 6mo ago −8.36%α −11.52% · $15.24
- T+60 · 4mo ago +39.03%α +34.25% · $23.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nurix Therapeutics presented new preclinical data at AACR 2026 across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972, highlighting deeper biological responses and synergy over existing inhibitors. The data reinforce the company's scientific leadership in targeted protein degradation but do not include clinical efficacy results. An upcoming AACR Advances session features Nurix’s CSO discussing clinical translation of degraders.
Key Facts
- Presented preclinical data for NRX-0305 showing 142% increase in lifespan vs. 12% for approved BRAF inhibitor in melanoma brain metastasis model.
- NX-1607 demonstrated single-agent anti-tumor activity and synergy with anti-PD-1 in multiple syngeneic models; early clinical data show target engagement via pHS1 modulation.
- NRX-4972 achieved 60% survival in SCLC model vs. 0% for AURKA inhibitors alisertib and LY3295668.
- No clinical efficacy data reported; all results are preclinical or early-phase biomarker signals.
- Insider sold $124K in the past 30 days, minimal but notable given lack of commercial-stage assets.
Financial Impact
No direct financial impact from this release; pipeline remains preclinical or early-phase. Market cap remains $1.7B, reflecting high expectations for degrader platform.
Risk Factors
- High reliance on unproven degrader modality; clinical translation remains uncertain.
- Preclinical results may not replicate in human trials.
- Limited near-term revenue potential; dependent on partnerships or future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278794 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers